One of the key policy areas of focus for the BIA is pre-clinical research. The use of animals is a key part of research in the safe and efficient development of medicines, and is a legal obligation for researchers. The BIA are signatories of the Concordat on Openness on the Use of Animals in Research, an agreement which promotes transparency and understanding of animals in research. Good science and good animal welfare go hand-in-hand, and this video from the Wellcome Trust highlights just how important the use of animals is when researchers seek to unravel the complexities of disease and human biology.
A key part of the BIA’s work on the Spending Review (SR) is engaging parliamentarians, who have a role in scrutinising and approving the Government’s decisions. To start this process, two weeks ago we teamed up with partner organisations across the life sciences sector to organise an event in the House of Commons – “Keeping the UK a world leader in medical research: the need for cross-government coordination”.
BIA Chair Jane Osbourn has announced this week that she is to leave Astra Zeneca after 25 years with Cambridge Antibody Technology and MedImmune. During that time she has achieved a huge amount of biological drug development, with 8 drugs launched, and biologics now making up 50% of the AZ pipeline. Jane will help with organisational transition at AZ for the next few months and has assured the BIA Board that she will continue as BIA Chair until the end of her term. Jane’s news follows AZ’s announcement (alongside their annual results last week) that it will be restructuring the R&D organisation to align with therapy areas.
We are delighted to launch our very own Brexit microsite today. The microsite shows the important work that the BIA has done in this crucial area and highlights the issues that matter most to our members.
Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.
Super-fast product addresses critical unmet need in development of next generation
artificial pancreas systems”
“Novel formulation significantly accelerates absorption of insulin post injection - accelerating the onset of glucose lowering.”
RxCelerate, one of the leading outsourced drug discovery and development platforms in the United Kingdom, announced today that it has acquired U.K.-based molecular modelling company Prosarix. Originally founded in 2006, Prosarix has built a reputation as one of the leading exponents of molecular modelling, supporting both protein engineering and in silico drug design projects.
When Brexit seemingly takes up an ever-increasing amount of time and resources, it’s important (and perhaps even – dare I say it – refreshing) to remember there are other matters of great concern for the life sciences sector.
One of those matters is this year’s Spending Review (SR)– the process by which the Government decides how much each government department will spend within a given period. This has a major impact on our sector as public funding bodies, such as UK Research and Innovation (UKRI), its Councils and the National Institute for Health Research (NIHR), are funded through government departments.